PUBLICATIONS

Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA
Justine Bacchetta, Claus Peter Schmitt, Gema Ariceta, Sevcan A. Bakkaloglu, Jaap Groothoff, Mandy Wan, Marc Vervloet, Rukshana Shroff and Dieter Haffner, Nephrol Dial Transplant (2019)
 
Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease
Pablo A Ureña-Torres Marc Vervloet Sandro Mazzaferro
Clinical Kidney Journal, 20 July 2018
 
Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population
Adrian Covic, Marc Vervloet, Ziad A Massy, Pablo Ureña Torres, David Goldsmith, Vincent Brandenburg, Sandro Mazzaferro, Pieter Evenepoel, Jordi Bover, Mugurel Apetrii, Mario Cozzolino
October 16, 2017
 
Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?
Sandro Mazzaferro, Ziad A. Massy, Marc Vervloet, Mario Cozzolino
J Nephrol 30 (5): 621-622 2017
 
The role of phosphate in kidney disease
Marc G. Vervloet, Siren Sezer, Ziad A. Massy, Lina Johansson, Mario Cozzolino, Denis Fouque
on behalf of the ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group, Nature Reviews Nephrology volume 13, pages 27–38 (2017)
 
Uremic Toxicity and Bone in CKD
Suguru Yamamoto, Masafumi Fukagawa,J Nephrol 30 (5): 623-627 2017
 
Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease
Ziad Massy, Tilman Drueke, J Nephrol 30 (5): 629-634 2017
 
The use of bone mineral density measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed microtomography in chronic kidney disease
Martin Jannot, Fabrice Mac-Way, Vanessa Lapierre, Marie-Helene Lafage-Proust, J Nephrol 30 (5):635-643 2017
 
Update on the role of bone biopsy in the management of patients with CKD–MBD
P. Evenepoel, G. J. S. Behets, M. R. Laurent, P. C. D’Haese, J Nephrol 30 (5):645-652 2017
 
Evaluation of fracture risk in chronic kidney disease
Pablo Antonio Ureña Torres, Martine Cohen-Solal, J Nephrol 30 (5): 653-661 2017
 
Circulating markers of bone turnover
Marc G. Vervloet, Vincent M. Brandenburg, J Nephrol 30 (5):663-670 2017
View Article

______________________________________________

Vitamin D in CKD
k

Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease
Mario Cozzolino, Pieter Evenepoel, Adrian Covic
p57
View Abstract

The Role of Klotho on Vascular Calcification and Endothelial Function in Chronic Kidney Disease
Marc G. Vervloet, Aaltje Y. Adema, Tobias E. Larsson, Ziad A. Massy
p578–58
View Abstract

New Insights Into the FGF23-Klotho Axis
Hannes Olauson, Marc G. Vervloet, Mario Cozzolino, Ziad A. Massy, Pablo Ureña Torres, Tobias E. Larsson
p586–597
View Abstract

News on Biomarkers in CKD‐MBD
Sandro Mazzaferro, Lida Tartaglione, Silverio Rotondi, Jordi Bover, David Goldsmith, Marzia Pasquali
p598–611
View Abstract

When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease
Pablo Ureña Torres, Jordi Bover, Sandro Mazzaferro, Marie Christine de Vernejoul, Martine Cohen-Solal
p612–625
View Abstract

Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease
Jordi Bover, Pablo Ureña, Vincent Brandenburg, David Goldsmith, César Ruiz, Iara DaSilva, Ricardo J. Bosch
p626–640
View Abstract

Calcific Uremic Arteriolopathy: A Call for Action
Vincent M. Brandenburg, Mario Cozzolino, Sandro Mazzaferro
p641–647
View Abstract

Calcium-Sensing Receptor Activation in Chronic Kidney Disease: Effects Beyond Parathyroid Hormone Control
Ziad A. Massy, Lucie Hénaut, Tobias E. Larsson, Marc G. Vervloet
p648–659
View Abstract

The Uses and Abuses of Vitamin D Compounds in Chronic Kidney Disease–Mineral Bone Disease (CKD–MBD)
D.J.A. Goldsmith, Z.A. Massy, V. Brandenburg
p660–668
View Abstract

 

Current Vascular Pharmacology

Editorial ( Thematic issue :VITAMIN D THERAPY: AN UPDATE Available Experimental and Clinical Evidences to Select “ Which D for Which Patient”); Pp: 271 - 271
Sandro Mazzaferro and Mario Cozzolino
Download Free

Update on the Biologic Role of the Vitamin D Endocrine System; Pp: 272 - 277
Adriana S. Dusso
View Abstract

Pharmacologic Role of Vitamin D Natural Products; Pp: 278 - 285
Pablo Urena-Torres and Jean Claude Souberbielle
View Abstract

Calcifediol – More than the Stepchild of CKD-MBD Therapy?; Pp: 286 - 293
Vincent M. Brandenburg and Thilo Kruger
View Abstract

Therapeutic Use of Calcitriol; Pp: 294 - 299
Mariano Rodriguez, Juan R. Munoz-Castaneda and Yolanda Almaden
View Abstract

Clinical Uses of 1-alpha-hydroxycholecalciferol; Pp: 300 - 305
Marc Vervloet
View Abstract

Clinical Uses of 1-Alpha-Hydroxy-Ergocalciferol; Pp: 306 - 312
Jongha Park, Connie M. Rhee, Wei Ling Lau and Kamyar Kalantar-Zadeh
View Abstract

Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D2 (Paricalcitol); Pp: 313 - 323
J. Bover, I. DaSilva, M. Furlano, M.J. Lloret, M.M. Diaz-Encarnacion, J. Ballarin and M. Cozzolino
View Abstract

Clinical Uses of 22-Oxacalcitriol; Pp: 324 - 328
Masahide Mizobuchi and Hiroaki Ogata
View Abstract

Further Vitamin D Analogs; Pp: 329 - 338
Pasquali M., Tartaglione L., Rotondi S., Leonangeli C. and Mazzaferro S.
View Abstract

Vitamin D Metabolites and/or Analogs: Which D for Which Patient?; Pp: 339 - 349
S. Mazzaferro, D. Goldsmith, T.E. Larsson, Z.A. Massy and M. Cozzolino
View Abstract

 

image5